Open-label, single-group Phase II pilot (n=38) testing two IV ketamine infusions (0.5 mg/kg each, 40 min, at H0 and H24) plus Good Psychiatric Management in adults with severe BPD; primary outcome at day 9 (BSL-23).
This pilot evaluates change in BPD symptom severity (BSL-23) at day 9 after two intravenous ketamine infusions (0.5 mg/kg over 40 minutes at H0 and H24) delivered alongside Good Psychiatric Management.
Participants are monitored for suicidal ideation, depressive symptoms, healthcare use, and adverse events with follow-up visits through three months; vital signs and AEs are assessed around each infusion.
Two intravenous ketamine infusions (0.5 mg/kg each) at H0 and H24, 40-minute infusion; delivered with standard-of-care Good Psychiatric Management.
Each infusion over 40 minutes; vitals and AEs monitored.